Lung Cancer Clinical Trial 20193593

[LCID Study Number: 20193593]

Immune Checkpoint Inhibitor Therapy Toxicity Bio-repository in Lung Cancer

The purpose of this study is to establish a bio-repository for future evaluation of predictive biomarkers of immune related adverse events (irAEs) in stage IV lung cancer patients receiving immune checkpoint inhibitors (ICI) as a single agent, in combination with other ICI, or with chemotherapy at Lahey.

Disease/Condition: Lung Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: Sanjna.Das@lahey.org